TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Diagnosis of T2DM prior to informed consent~2. Male and female patients on diet and exercise regimen who are pre-treated with multiple daily injections (MDI) of insulin alone or in combination with immediate or extended release metformin~3. Stable metformin therapy: daily dose \>=1500 mg/day or maximum tolerated dose~4. HbA1c \>=7.5% and \<=10% at screening~Exclusion criteria:~1. Uncontrolled hyperglycemia with a glucose level \>240 mg/dl (\>13.3 mmol/L) after an overnight fast during placebo run-in~2. Any contraindications to metformin according to the local label~3. Acute coronary syndrome, stroke or TIA within 3 months prior to informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BI 10773 low dose (Type: EXPERIMENTAL): BI 10773 low dose once daily
- BI 10773 high dose (Type: EXPERIMENTAL): BI 10733 high dose once daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets matching BI 10773

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Diclofenac Capsules to Treat Osteoarthritis Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Primary diagnosis of Functional Class I-III OA of the hip or knee with documented osteoarthritis flare at baseline~* Chronic user of nonsteroidal anti-inflammatory drugs (NSAIDs) and/or acetaminophen for OA pain~* Discontinued all analgesic therapy at Screening~* For women of child-bearing potential: a woman who is not pregnant and not nursing, and who is practicing an acceptable method of birth control~Exclusion Criteria:~* History of allergic reaction or clinically significant intolerance to acetaminophen, aspirin, or any NSAIDS, including diclofenac~* Requires continuous use of opioid or opioid combination products to control OA pain of the knee or hip~* Clinically significant unstable cardiac, respiratory, neurological, immunological, hematological, or renal disease~* Significant difficulties swallowing capsules or unable to tolerate oral medication~* Previous participation in another clinical study of Diclofenac Capsules or received any investigational drug or device or investigational therapy within 30 days before Screening.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Diclofenac Capsules 35 mg bid (Type: EXPERIMENTAL): None
- Diclofenac Capsules 35 mg tid (Type: EXPERIMENTAL): None
- Placebo Capsule (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Saline Hypertonic in Preschoolers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of CF as evidenced by one or more clinical feature consistent with the CF phenotype or positive CF newborn screen AND one or more of the following criteria:~* A documented sweat chloride ≥ 60 milliequivalents of solute per litre (mEq/L) by quantitative pilocarpine iontophoresis (QPIT)~* A documented genotype with two disease-causing mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene~* Informed consent by parent or legal guardian~* Age ≥ 36 months and ≤72 months at Screening visit~* Ability to comply with medication use, study visits and study procedures as judged by the site investigator~* Ability to perform technically acceptable MBW measurements at the screening and enrollment visits~Exclusion Criteria:~* Acute intercurrent respiratory infection, defined as an increase in cough, wheezing, or respiratory rate with onset within 3 weeks preceding Screening or Enrollment visit~* Acute wheezing at Screening or Enrollment visit~* Oxygen saturation \< 95% (\<90% in centers located above 4000 feet elevation) at Screening or Enrollment visit~* Physical findings that would compromise the safety of the participant or the quality of the study data as determined by site investigator~* Investigational drug use within 30 days prior to Screening or Enrollment visit~* Treatment with inhaled hypertonic saline at any concentration within 30 days prior to Screening or Enrollment visit~* Chronic lung disease not related to CF~* Inability to tolerate first dose of study treatment at the Enrollment visit

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Active Treatment Group (Type: EXPERIMENTAL): 7% Hypertonic Saline administered via inhalation twice daily for 48 weeks
- Control Group (Type: ACTIVE_COMPARATOR): 0.9% Isotonic Saline administered via inhalation twice daily for 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Spreading Depolarization and Ketamine Suppression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* GCS \<8~* SAH or severe traumatic brain injury requiring craniotomy~* Consent obtainable (via legal representative)~* Ictus (bleed or injury) within 48 hours of enrollment~* Clinically appropriate for multimodality monitoring~Exclusion Criteria:~* Anticipated survival \<48 hours~* No craniotomy~* Infratentorial craniotomy only•Unable to obtain consent~* Absence of clinically used multimodality monitoring~* Prisoners~* Pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Ketamine first (Type: EXPERIMENTAL): Randomization to receive ketamine as first post-operative sedative in the Neuroscience Intensive Care unit. This group will cross-over to other sedation after 6 hours, then alternate every 6 hours between these groups during the entirety of invasive neuromonitoring.
- Other sedation (typically propofol) first (Type: EXPERIMENTAL): Randomization to receive sedative other than ketamine as first post-operative sedative in the Neuroscience Intensive Care unit. This group will cross-over to ketamine after 6 hours, then alternate every 6 hours between these groups during the entirety of invasive neuromonitoring.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Co-trimoxazole as Maintenance Therapy for Melioidosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 15 years~2. Culture-confirmed melioidosis~3. Currently on oral co-trimoxazole for 12(+2) weeks without any clinical evidence of active melioidosis~4. High likelihood of completing at least 6 months follow up~5. Willingness to participate in the study and written, informed consent obtained from the patient~Exclusion Criteria:~1. Pregnancy or breast feeding~2. Contraindications to TMP-SMX: G6PD, severe adverse reactions grade 3-4 occurring during first 12 weeks of treatment~3. Relapse melioidosis with at least 2 year symptom free period from last episode

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Co-trimoxazole 12 (Type: ACTIVE_COMPARATOR): Receive treatment with co-trimoxazole for 12 weeks.
- Co-trimoxazole 20 (Type: EXPERIMENTAL): Receive treatment with co-trimoxazole for 20 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Detection, Education, Research and Decolonization Without Isolation in Long-term Care Facilities

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All patients in 18 LTCF nursing units randomly selected as intervention or control units~Exclusion Criteria:~* Patients that choose not to be included in the program

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: None): Active surveillance testing for MRSA and decolonization of positive subjects
- control (Type: None): Usual standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Efficacy of Extended Release Tacrolimus (Advagraf®) + Sirolimus (Rapamune®), Versus Extended Release Tacrolimus (Advagraf®) + Mycophenolate Mofetil in Kidney Transplant Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients aged over 20 years~* Patient who is judged would have the benefits of the Extended Release Tacrolimus (Advagraf®)treatment by the investigator~* Patients has given written informed consent~* Patient is a recipient of primary or recipient of primary (a living kidney transplant, a cadaveric donor.)~* Patients has received an ABO compatible donor kidney.~* Complement-dependent Cytotoxic Crossmatch: CDC) result: negative~* Female patients of child bearing potential must have a negative urine or serum pregnancy test within 7 days prior to enrollment or upon hospitalization~Exclusion Criteria:~* Patient has previously received an organ transplant other than a kidney.~* Patient has a known hypersensitivity to tacrolimus, Sirolimus (Rapamune®),Mycophenolate mofetil.~* Desensitization~* HLA-identical~* Heart Disease; Heart failure (symptom, EF \<45%)~* Lung Disease; Significant chronic obstructive pulmonary disease, restrictive lung disease~* Patient has an uncontrolled concomitant infection (including Hepatitis B, Hepatitis C) or any other unstable~* malignant tumor history in the 5years prior to enrollment. (except,squamous cell carcinoma)~* Patient has received a kidney transplant from non-heart beating donor~* Cold ischemic time \> 30hrs~* Elevated AST and/or ALT levels greater than 3 times the upper value of the normal range of the investigational site~* (ANC)\<1,500/mm3, (WBC)\<2,500/ mm3, (PLT)\<100,000/ mm3~* ATG: Anti-thymocyte globulin induction~* Medical condition that could interfere with the study objectives.~* Patient is currently taking or has been taking an investigational products in the 30 days prior to enrollment.~* Patient is currently taking or has been taking an prohibited medications in the 28 days prior to enrollment.~* Patient who is judged not to be adequate by the investigator owing to other reasons~* Patient is pregnant or lactating.~* Recipient or donor is known to be seropositive for human immunodeficiency virus.(HIV)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A) TEST (Type: ACTIVE_COMPARATOR): None
- B) CONTROL (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Oral Febuxostat in Subjects With Gout

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Hyperuricemia (serum urate ≥8.0 mg/dL) and gout by Chinese Rheumatism Association Criteria;~* Renal function defined as a serum creatinine level of \< 2.0 mg/dL and creatinine clearance of \> 20 milliliters per minute (mL/min) by Cockcroft and Gault formula;~* No gout flare 2 weeks beforehand during 2-week screening period.~Exclusion Criteria:~* Pregnancy or lactation;~* Concurrent therapy with urate lowering agents, azathioprine, 6-mercaptopurine, thiazide diuretics, or medications containing aspirin (\>325 mg) or other salicylates;~* Body Mass Index (BMI) \>50 kilogram per meter²(kg/m²);~* A history of active liver disease, or hepatic dysfunction;~* A history of bronchial asthma;~* A history of renal calculi or thyroid disease;~* Secondary gout Joint diseases induced by rheumatoid arthritis, psoriatic arthritis and bone tumor;~* Intolerance to allopurinol and Ibuprofen;~* Alcohol intake of ≥ 14 drinks/week;~* Clinically significant medical condition.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Febuxostat 40 mg QD (Type: EXPERIMENTAL): Febuxostat 40 mg, orally, once daily for up to 24 weeks
- Febuxostat 80 mg QD (Type: EXPERIMENTAL): Febuxostat 80 mg, orally, once daily for up to 24 weeks
- Allopurinol 100mg QD (Type: ACTIVE_COMPARATOR): Allopurinol 100mg, orally, three times daily for up to 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: International Multicenter, Observational, Non-Interventional Prospective Study of Azilsartan Medoxomil in Participants With Arterial Hypertension Who Are Overweight or Obese in the Russian Federation and The Republic of Kazakhstan

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Male and female participants ≥ 18 years of age with hypertension 1-2 grade.~2. Participants with:~   * newly diagnosed arterial HTN or~  * inadequately controlled previously prescribed monotherapy with Renin-Angiotensin-Aldosterone System (RAAS) blocker or~  * inadequately controlled previously prescribed combination therapy with RAAS blocker + diuretic or RAAS blocker + calcium antagonist.~3. The physician decides to prescribe Edarbi®~   * as monotherapy or~  * as a part of combination therapy including diuretics or calcium antagonists;~4. Overweight or obesity of any degree (body mass index\> 25 kg/m\^2);~5. Is capable of understanding the written informed consent, provides signed and written informed consent, and agrees to comply with protocol requirements. In case the participant is blind or unable to read, informed consent will also be witnessed.~Exclusion Criteria:~1. Confirmed secondary HTN;~2. Contraindications for Edarbi® of respective approved local summary of product characteristics (SmPC) of Edarbi®;~3. Any reasons of medical and non-medical character, which in the opinion of the physician can prevent participant participation in the study.~4. Is an employee or family member of the investigator or study site personnel.~5. Is currently participating in a clinical trial. Participation in non-interventional registries is permitted.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azilsartan Medoxomil (Type: None): Overweight or obese participants with hypertension who received azilsartan medoxomil tablets, orally, as prescribed by physician according to local summary of product characteristics (SmPC) were observed for approximately 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Routine Therapy Plus Moxifloxacin in Advanced Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female ≥ 18 years, ≤70 years.~* Has measurable metastatic MBC, with at least 1 measurable lesion per RECIST criteria.~* Fail first-line or above anti-tumor treatment~* Evaluation is stable disease with a trend of progression.~* Minimum life expectancy 16 weeks~* Histological confirmation of breast cancer on primary tumour at diagnosis/on biopsy of metastasis~* ECOG Performance Status (PS) 0-2 with no deterioration over previous 2 weeks~* Normal organ function.~* Has signed a Patient Informed Consent Form~Exclusion Criteria:~* Hypersensitivity to moxifloxacin or other quinolones.~* Tendon damage,peripheral neuropathy,myasthenia gravis.~* Rapidly progressive visceral disease not suitable for further therapy.~* Evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or active infection including hepatitis B, hepatitis C and HIV~* With the exception of alopecia, any unresolved toxicities from previous therapy greater than CTCAE grade 1 before study treatment~* Evidence of dementia, altered mental status or any psychiatric condition that would prohibit understanding or rendering of informed consent~* Inability or unwillingness to comply with study procedures, including inability to take regular oral medication~* Researchers consider it is not suitable for participation.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- routine therapy plus moxifloxacin (Type: EXPERIMENTAL): Routine therapy (chemotherapy, endocrine therapy or target therapy) is according to physician's choice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients with CFS~* age 18-66 years~* informed consent~Exclusion Criteria:~* patients with fatigue, not fulfilling criteria for CFS~* pregnancy or lactation~* previous malignant disease except basal cell carcinoma of skin and cervical carcinoma in situ~* previous major immunological disease, except autoimmune diseases such as diabetes mellitus or thyroiditis~* previous long-term use of immunosuppressive drugs, except steroids e.g. in obstructive lunge disease~* endogenous depression~* lack of ability to comply by the protocol~* multi-allergy with risk of serious drug reaction~* reduced renal function (creatinin \> 1.5 x UNL)~* reduced liver function (bilirubin or transaminases \> 1.5 x UNL)~* HIV positivity~* evidence of clinically significant infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 66 Years
- Healthy Volunteers: f

Study Arms:
- Rituximab (Type: EXPERIMENTAL): Rituximab induction using two infusions (500mg/m2, max 1000 mg) two weeks apart, followed by maintenance Rituximab infusions (500 mg/m2, max 1000 mg) after 3, 6, 10 and 15 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* obese (body mass index \[BMI\] ≥30 kg/m² and ≤40 kg/m²) male participants and female participants of non-childbearing potential~* has been diagnosed with T2D (Panel B)~* is not actively participating in a weight loss program~Exclusion Criteria:~* has a history of clinically-significant disease (other than T2D)~* has a history of cancer~* has estimated creatinine clearance ≤60 mL/min~* is unable to refrain from or anticipates the use of any prescription or non-prescription medication~* consumes excessive amounts of alcohol or caffeine~* has participated in a previous omarigliptin study

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Healthy Omarigliptin (Type: EXPERIMENTAL): Obese healthy participants receive once-weekly omarigliptin 50 mg by mouth for 4 weeks (Panel A).
- Healthy Placebo (Type: PLACEBO_COMPARATOR): Obese healthy participants receive once-weekly placebo by mouth for 4 weeks (Panel A).
- T2D Omarigliptin (Type: EXPERIMENTAL): Obese participants with T2D receive once-weekly omarigliptin 50 mg by mouth for 4 weeks (Panel B).
- T2D Placebo (Type: PLACEBO_COMPARATOR): Obese participants with T2D receive once-weekly placebo by mouth for 4 weeks (Panel B).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete